Mayewell Capital

John Zhu, the firm's Founder, President, CIO, and Managing Member, runs investment decisions. He is the sole named investment principal in firm communications. W. Wong is listed as a business partner through official corporate channels, though no specific investment role has been disclosed publicly.

John Zhu serves simultaneously as CEO and Founder of Ingenio Therapeutics, a separate operating company, while managing Mayewell Capital. The relationship is not formally structured as a family office or captive venture arm — the two entities share a common founder but operate under distinct corporate identities. This dual role gives Mayewell a diligence mechanism rooted in operating experience within the therapeutics sector.

The firm targets buyout, growth equity, and pre-IPO rounds according to its stated strategy. Confirmed transactions span venture-stage biotech — ThirtyFiveBio raised funding from Mayewell alongside AbbVie Ventures and Canaan — indicating the firm operates across early through late-stage private placements.

Yes. The firm holds Asia-Pacific drug rights as part of its asset base, and has co-invested alongside global pharmaceutical venture arms including Johnson & Johnson Innovation (JJDC). This suggests a cross-border investment posture focused on biopharmaceutical assets with international IP value.

Known co-investors include AbbVie Ventures, Canaan, and Johnson & Johnson Innovation (JJDC). These relationships emerged in specific therapeutics deals — ThirtyFiveBio and ONL Therapeutics — indicating that Mayewell accesses syndicates alongside established life-sciences venture firms and corporate venture arms.